The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.
4 reports, 4 independent
Updated Aug 15
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved the Oncomine Dx Target Test, which identifies candidates for Boehringer Ingelheim's HERNEXEOS.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Boehringer Ingelheim
German pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- ZacksTMO Receives FDA Approval for Oncomine Dx Target Test Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a compan
- Simply Wall St.Thermo Fisher Scientific (TMO) Oncomine Dx Test Gains FDA Approval for NSCLC Treatment Thermo Fisher Scientific has seen significant developments with the recent FDA approval of its Oncomine Dx Targe
- Medical Device NetworkFDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatme
- Business WireThermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS® (zong